Physician profile
Anthony Celifarco
NPI 1205839305
$7,040.03
in general payments reported to CMS, 2019-2025
33 companies · $1,687 in 2025
The $1,687 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.65 · 2020: $436 · 2021: $561 · 2022: $749 · 2023: $1,994 · 2024: $1,593 · 2025: $1,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,354 · Debt Forgiveness: $853 · Education: $27.63 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,354.12 |
| Debt Forgiveness | $852.74 |
| Education | $27.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,308.98 | 2020-2025 | Skyrizi, Rinvoq, Viberzi |
| Olympus America INC. | $852.74 | 2023 | Olympus |
| Janssen Biotech, INC. | $631.95 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $552.91 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Lilly USA, LLC | $543.44 | 2024-2025 | Omvoh, Zepbound, Mounjaro |
| Pfizer INC. | $501.80 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $489.11 | 2020-2025 | Xifaxan, Trulance |
| Ferring Pharmaceuticals INC. | $329.99 | 2020-2023 | Rebyota |
| Ardelyx, INC. | $220.45 | 2022-2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $200.12 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $198.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $183.89 | 2020-2024 | Talicia |
| Celgene Corporation | $159.09 | 2021-2024 | Zeposia |
| Genzyme Corporation | $139.52 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $131.77 | 2022-2025 | Ocaliva |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $101.64 | 2023-2025 | Vowst |
| Nestle Healthcare Nutrition INC. | $67.86 | 2020-2021 | |
| Braintree Laboratories, INC. | $67.71 | 2020-2023 | Suflave |
| Intra-Sana Laboratories | $59.63 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Merck Sharp & Dohme LLC | $31.50 | 2020 | |
| Alfasigma USA, INC. | $28.45 | 2020 | |
| Celltrion USA INC. | $27.63 | 2024 | Zymfentra |
| Perspectum Diagnostics LTD | $26.34 | 2023 | Livermultiscan |
| Exact Sciences Corporation | $25.30 | 2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $23.08 | 2020 | |
| Gilead Sciences, INC. | $21.36 | 2020 | |
| Novo Nordisk INC | $20.31 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $19.89 | 2021 | |
| Enterra Medical, INC. | $19.37 | 2023 | |
| Allergan, INC. | $15.32 | 2020 | |
| Medtronic, INC. | $13.75 | 2023 | Gi Genius |
| Capsovision, INC. | $13.26 | 2024 | Capsocam Plus |
| Evoke Pharma, INC. | $13.23 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Celifarco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.